OGN: Organon & Co. Stock

by  •  • Comments Off on OGN: Organon & Co. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 4,365.11
Enterprise Value ($M) 12,769.11
Book Value ($M) -737.00
Book Value / Share -2.88
Price / Book -5.92
NCAV ($M) -7,576.00
NCAV / Share -29.64
Price / NCAV -0.58

Profitability (mra)
Return on Invested Capital (ROIC) 0.09
Return on Assets (ROA) 0.07
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 1.16
Current Ratio 1.66

Balance Sheet (mrq) ($M)
Current Assets 3,958.00
Assets 10,979.00
Liabilities 11,534.00
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-13 13G Mawer Investment Management Ltd. 5.39
02-10 13G State Street Corp 5.06
02-09 13G/A Vanguard Group Inc 12.37 9.37
02-07 13G/A BlackRock Inc. 6.40 -3.03

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2023-08-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PU
2023-05-05 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT P
2023-02-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K
2022-11-04 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2023-09-29 411,485 3,237,091 12.71
2023-09-28 479,536 4,098,719 11.70
2023-09-27 852,350 6,085,563 14.01
2023-09-26 1,009,281 5,360,546 18.83

(click for more detail)

Similar Companies
MRK – Merck & Co Inc MYOV – Myovant Sciences Ltd
NUVB – Nuvation Bio Inc – Class A PBH – Prestige Consumer Healthcare Inc
PFE – Pfizer Inc.


Financial data and stock pages provided by
Fintel.io